DocDollars

Syndax Pharmaceuticals, Inc.

NY · United States · Reporting entity ID 100001453597

Total reported 2019–2025
$13.2M
#422 of 2,960 reporting companies — 0% of all reported industry payments
$4.53M in general payments across 5,560 records, plus $8.64M in research funding across 695 records.

How it breaks down

General payments $4,530,046
Research funding $8,642,040

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Syndax Pharmaceuticals, Inc. reported $13.2M to US doctors and teaching hospitals from 2019 to 2025, ranking #422 of 2,960 reporting companies. 66% of that was research funding and 34% general payments such as consulting, speaking, food and travel. 5,560 general payment records and 695 research records were filed.

Common questions about Syndax Pharmaceuticals, Inc.

How much has Syndax Pharmaceuticals, Inc. paid US doctors?

Syndax Pharmaceuticals, Inc. reported $13,172,086 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $4,530,046 in general payments, $8,642,040 in research funding.

How does Syndax Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #422 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Syndax Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.